Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

May 21, 2024 updated by: Otsuka Pharmaceutical Development & Commercialization, Inc.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
136

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Bulgaria
      • Kazanlak, Bulgaria, 6100
        • Clinical Research Site #009
      • Novi Iskar, Bulgaria, 1282
        • Clinical Research Site #100-008
      • Plovdiv, Bulgaria, 4004
        • Clinical Research Site #100-007
      • Sofia, Bulgaria, 1680
        • Clinical Research Site #100-004 2
      • Veliko Tarnovo, Bulgaria, 5000
        • Clinical Research Site #100-006
      • Vratsa, Bulgaria, 3000
        • Clinical Research Site #100-001
  • Poland
      • Bełchatów, Poland, 97-400
        • Clinical Research Site #616-002
      • Pruszcz Gdański, Poland, 80-300
        • Clinical Research Site #616-003
    • Woj.Iodzkie
      • Tuszyn, Woj.Iodzkie, Poland, 95-080
        • Clinical Research Site
  • Puerto Rico
      • San Juan, Puerto Rico, 918
        • Clinical Research Site #630-001
      • San Juan, Puerto Rico, 926
        • Clinical Research Site # 630-002
  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72209
        • Clinical Research Site
    • California
      • Anaheim, California, United States, 92805
        • Clinical Research Site #840-041
      • Bellflower, California, United States, 90706
        • Clinical Research Site #840-013
      • Costa Mesa, California, United States, 92626
        • Clinical Research Site #840-079
      • Culver City, California, United States, 90230
        • Clinical Research Site #840-027
      • Garden Grove, California, United States, 92845
        • Clinical Research Site #840-006
      • Glendale, California, United States, 91206
        • Clinical Research Site #840-026
      • La Habra, California, United States, 90631
        • Clinical Research Site# 840-067
      • Lafayette, California, United States, 94549
        • Clinical Research Site# 840-083
      • Lemon Grove, California, United States, 91945
        • Clinical Research Site 840-002
      • Oakland, California, United States, 94607
        • Clinical Research Site
      • Oceanside, California, United States, 92056
        • Clinical Research Site #840-035
      • Panorama City, California, United States, 91402
        • Clinical Research Site# 840-010
      • Riverside, California, United States, 92506
        • Clinical Research Site #840-012
      • San Bernardino, California, United States, 92408
        • Clinical Research Site# 840-081
      • San Diego, California, United States, 92102
        • Clinical Research Site #840-005
      • Santee, California, United States, 92071
        • Clinical Research Site #840-096
      • Torrance, California, United States, 90502
        • Clinical Research Site #840-015
    • Florida
      • Doral, Florida, United States, 33178
        • Clinical Research Site# 840-094
      • Hollywood, Florida, United States, 33021
        • Clinical Research Site #840-046
      • Homestead, Florida, United States, 33030
        • Clinical Research Site Site #840-093
      • Lakeland, Florida, United States, 33803
        • Clinical Research Site #840-062
      • Largo, Florida, United States, 33770
        • Clinical Research Site #840-024
      • Miami, Florida, United States, 33122
        • Clinical Research Site #840-032
      • Miami, Florida, United States, 33173
        • Clinical Research Site #840-080
      • Miami Lakes, Florida, United States, 33014
        • Clinical Research Site #840-084
      • Okeechobee, Florida, United States, 34972
        • Clinical Research Site
      • Weston, Florida, United States, 33331
        • Clinical Research Site # 840-102
    • Georgia
      • Atlanta, Georgia, United States, 30303
        • Clinical Research Site #840-088
      • Atlanta, Georgia, United States, 30318
        • Clinical Research Site #840-091
      • Atlanta, Georgia, United States, 30328
        • Clinical Research Site #840-008
      • Decatur, Georgia, United States, 30030
        • Clinical Research Site #840-063
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Clinical Research Site
      • Springfield, Illinois, United States, 62702
        • Clinical Research Site #840-090
    • Louisiana
      • Lake Charles, Louisiana, United States, 70629
        • Clinical Research Site
      • Shreveport, Louisiana, United States, 71101
        • Clinical Research Site #840-098
    • Massachusetts
      • Worcester, Massachusetts, United States, 01605
        • Clinical Research Site #840-072
    • Mississippi
      • Flowood, Mississippi, United States, 39232
        • Clinical Research Site #840-057
    • Missouri
      • Olivette, Missouri, United States, 63132
        • Clinical Research Site #840-040
      • Saint Charles, Missouri, United States, 63304
        • Clinical Research Site #840-029
      • Saint Charles, Missouri, United States, 63304
        • Clinical Research Site #840-034
      • Saint Louis, Missouri, United States, 63109
        • Clinical Research Site
      • Saint Louis, Missouri, United States, 63118
        • Clinical Research Site #840-025
    • New Jersey
      • Berlin, New Jersey, United States, 08009
        • Clinical Research Site #840-028
    • New York
      • Jamaica, New York, United States, 11432
        • Clinical Research Site #840-009
      • New York, New York, United States, 10027
        • Clinical Research Site #840-070
      • Rochester, New York, United States, 14618
        • Clinical Research Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28211
        • Clinical Research Site #840-074
    • Ohio
      • Middleburg Heights, Ohio, United States, 44130
        • Clinical Research Site #840-052
    • Oklahoma
      • Edmond, Oklahoma, United States, 73013
        • Clinical Research Site
      • Oklahoma City, Oklahoma, United States, 73112
        • Clinical Research Site #840-065
    • Pennsylvania
      • Media, Pennsylvania, United States, 19063
        • Clinical Research Site #840-061
      • Norristown, Pennsylvania, United States, 19401
        • Clinical Research Site
    • South Carolina
      • Myrtle Beach, South Carolina, United States, 28117
        • Clinical Research Site #840-099
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Clinical Research Site
    • Texas
      • DeSoto, Texas, United States, 75115
        • Clinical Research Site
      • Fort Worth, Texas, United States, 76104
        • Clinical Research Site #840-058
      • Richardson, Texas, United States, 75080
        • Clinical Research Site #840-018
      • San Antonio, Texas, United States, 78229
        • Clinical Research Site
    • Utah
      • Springville, Utah, United States, 84663
        • Clinical Research Site #840-069
    • Washington
      • Everett, Washington, United States, 98201
        • Clinical Research Site #840-051

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Participants who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2
  • Participants must have well-controlled positive symptoms and prominent negative symptoms as defined by Positive and Negative Syndrome Scale (PANSS) criteria.
  • Participants currently receiving a second-generation atypical antipsychotic drug (SGA) are eligible if they are stable and adherent to their dosing schedule.
  • Participants must have a reliable informant (e.g., case manager, social worker, family member). The informant should be able to spend an adequate amount of time with the participant to be able to address behaviors, activities, and symptoms.

Exclusion Criteria:

  • Participants with current major depressive disorder (MDD)
  • Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication
  • Participants currently using anticholinergic medications
  • Participants recently hospitalized as in-patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: Placebo
Placebo capsules will be administered orally twice a day over a 15-week period.
Drug: Placebo
oral capsules
Experimental: AVP-786
AVP-786 capsules will be administered orally twice a day over a 15-week period.
Drug: AVP-786
oral capsules

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Change from Baseline to Week 15 in the Positive and Negative Syndrome Scale (PANSS) Marder Negative Factors Score
Time Frame: Baseline; Week 15
Baseline; Week 15

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Change from Baseline to Week 15 in the Negative Symptom Assessment-16 (NSA-16) Global Negative Symptom Score
Time Frame: Baseline; Week 15
Baseline; Week 15
Change from Baseline to Week 15 in the Patient Global Impression of Severity (PGI-S) Score
Time Frame: Baseline; Week 15
Baseline; Week 15
Change from Baseline to Week 15 in the Patient Global Impression of Change (PGI-C) Score
Time Frame: Baseline; Week 15
Baseline; Week 15

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 15, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 23, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 23, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 19, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 28, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 1, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 24, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 21, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 18-AVP-786-207
  • 2021-001352-33 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

IPD Sharing Time Frame

Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

IPD Sharing Access Criteria

Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings